Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study.
Arai T, Atsukawa M, Tsubota A, Ono H, Kawano T, Yoshida Y, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Nagao M, Iwakiri K. Arai T, et al. Among authors: tsubota a. JGH Open. 2022 Jun 16;6(7):503-511. doi: 10.1002/jgh3.12780. eCollection 2022 Jul. JGH Open. 2022. PMID: 35822119 Free PMC article.
An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C. Kondo C, et al. Among authors: tsubota a. J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9. J Viral Hepat. 2012. PMID: 22863265 Clinical Trial.
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C. Atsukawa M, et al. Among authors: tsubota a. J Gastroenterol Hepatol. 2013 Jan;28(1):51-6. doi: 10.1111/j.1440-1746.2012.07267.x. J Gastroenterol Hepatol. 2013. PMID: 22989264 Clinical Trial.
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C. Itokawa N, et al. Among authors: tsubota a. J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039. J Gastroenterol Hepatol. 2013. PMID: 23173698 Clinical Trial.
α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.
Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. Shimada N, et al. Among authors: tsubota a. J Med Virol. 2014 Mar;86(3):461-72. doi: 10.1002/jmv.23824. Epub 2013 Oct 28. J Med Virol. 2014. PMID: 24166425
Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: tsubota a. Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013. Hepat Mon. 2013. PMID: 24403915 Free PMC article.
Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: tsubota a. Hepatol Res. 2014 Dec;44(13):1277-85. doi: 10.1111/hepr.12298. Epub 2014 Feb 26. Hepatol Res. 2014. PMID: 24417888
A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.
Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M. Shimada N, et al. Among authors: tsubota a. Hepatol Res. 2014 Dec;44(14):E386-96. doi: 10.1111/hepr.12323. Epub 2014 Apr 15. Hepatol Res. 2014. PMID: 24606109
Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: tsubota a. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):781-7. doi: 10.1097/MEG.0000000000000105. Eur J Gastroenterol Hepatol. 2014. PMID: 24732752 Clinical Trial.
316 results